News and Press Releases
Spur provides update on FLT201 and planned phase III clinical trial
8 July 2024 -- London, UK -- Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company...
Category: Clinical Trials, Other, Pharmaceutical
Posted: July 8, 2024
Stockholm 3 commercially available in the US
A3P Biomedical AB, a leading Swedish diagnostics company specializing in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, are excited to announce that Stockholm3 for early detection...
Category: Biotechnology
Posted: July 3, 2024
Phase 2b Influenza Field Study Contract
hVIVO to enrol up to 1,000 healthy volunteers as part of a multicentre field study testing an influenza drug candidate, with hVIVO selected as the sole UK clinical site Largest...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024
1nhaler hires pharma industry leaders for key roles ahead of clinical trials
Edinburgh-based 1nhaler has appointed two experts in inhalation and respiratory medicines to the board as it looks to accelerate the development and market-readiness of its novel single use inhaler device....
Category: Clinical Trials, Other
Posted: July 1, 2024
RYBREVANT (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Approval is supported by the phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60% compared to chemotherapy alone 28...
Category: Clinical Trials, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
CHMP adopts positive opinion for BALVERSA (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers The CHMP’s recommendation is based on results...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
New study investigates link between toxic element exposure and Alzheimer’s disease risk
25 June 2024 -- Malvern, UK -- A comprehensive study is currently underway to clarify the relationship between Alzheimer's disease and related dementias (AD/ADRD) and four toxic elements: lead, mercury, arsenic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 27, 2024
Prevention and early detection of gastrointestinal cancers take on new importance amidst a younger population
Emerging research on early-onset gastrointestinal cancers highlights need for better prevention, diagnosis and treatment Less invasive, smart technologies could improve participation in and efficacy of GI cancer screening Studies presented...
Category: Other
Posted: June 27, 2024
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials June 24 2024, California, US, -Bio-Rad Laboratories, Inc. (NYSE: BIO...
Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: June 24, 2024
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report
24 June 2024 -- Washington, DC -- Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 24, 2024
New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials
Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US --...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024
Medigene AG Announces Lead Selection for MDG2021,Expanding TCR-T KRAS Library Targeting Solid Tumours
20 June 2024, Planegg/Martinsried, Germany- Medigene AG (Medigene, the “company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Category: Drug Delivery
Posted: June 20, 2024
Bio-Rad Launches ddSEQ Single-Cell 3′ RNA-Seq Kit for Single-Cell Gene Expression
ddSEQ single-cell 3' RNA-Seq kit and Omnition v1.1 analysis software enable high-quality and affordable single-cell transcription and gene expression to support molecular biology, oncology and drug discovery research 19 June...
Category: Drug Discovery, Other, Pharmaceutical
Posted: June 19, 2024
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK - STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 17, 2024
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9...
Category: Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
